Replies to post #430368 on Anavex Life Sciences Corp (AVXL)

[McMagyar]

Ok
Let’s explain this one more time
Voucher for Quick review worth $100 million with zero cost.

Only get Voucher IF pediatric disease FIRST application of drug..


We will most likely NOT see NDA for Alzheimer’s until AFTER NDA for Rett Syndrome.

So .. would make more sense to root for Rett Data them NDA for AD..

Come on Rett data..